All In Biotech

Drug Trial Radar · NCT00280657

Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa

Multicenter, Double-blind, Double-dummy, Randomized Parallel Group Study to Evaluate the Safety and Efficacy of SH D 00659 E for 6 Treatment Cycles in Female Patients With Acne Papulopustulosa in Comparison to SH D 00659 G and Placebo.

Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,326

Actual

Start

Mar 10, 2004

Primary completion

May 21, 2005

Study completion May 21, 2005

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine safety and efficacy of an oral contraceptive in treating acne papulopustulosa.

Conditions

  • Acne Vulgaris

Interventions

  • ValetteDrug

    1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles

  • DianeDrug

    1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles

  • PlaceboDrug

    2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in lesionsTime frame: 6 months

Locations

62 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Čáslav, Czechia

  • Site not named

    Chomutov, Czechia

  • Site not named

    Kutná Hora, Czechia

  • Site not named

    Louny, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Slaný, Czechia

  • Site not named

    Svitavy, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Grudziądz, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Poznan, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Korolyov, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moskva, Russia

  • Site not named

    Moskva, Russia

  • Site not named

    Petrozavodsk, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Banská Bystrica, Slovakia

  • Site not named

    Bratislava, Slovakia

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.